Crinos Industria Farmacobiologica S.p.a.

Massachusetts Institute of Technology

Baxter International Inc.

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Sigma-tau Research Switzerland S.a.

Istituto Di Ricerche Chimiche E Biochimiche G Ronzoni

Grace Italiana S.p.a.

Montedison S.p.a.

Nicox S.a.

Sanofi Sa

Inalco S.p.a.

Crinos Industria Farmabiologica, S.p.a.

Instituto Di Ricerche Chimiche E Biochimiche G. Ronzoni

Benito Casu

Giangiacomo Torri

Annamaria Naggi

Ram Sasisekharan

Sergio Penco

Ganesh Venkataraman

Claudio Pisano

Giuseppe Giannini

Rahul Raman

Anna Maria Naggi

Marco Guerrini

Giorgio Zoppetti

Ennio Lanzarotti

Giuseppe Prino

Armando Cedro

Enrico Petrella

Fabio Tegiacchi

Piero Del Soldato

Francesca Benedini

Pasqua Anna Oreste

Roberto Porta

Giancarlo Sportoletti

Laura Ferro

Marisa Mantovani

Rodolfo Pescador

Francesco De Santis

Alberto Nicoletti

Simona Venturini

Paolo Gresele

Virginio Colombo

Mario Chiruzzi

Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and Rgroups have the meanings indicated in the description. These glycosaminoglycan derivatives exhibit antiangiogenic activity and are devoid of anticoagulant activity.

Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) 

Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.

Method for sequence determination using NMR

The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

Peritoneal dialysis solution containing modified icodextrins

The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups &#x2014;ONOcovalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and/or hexosamine, with subsituents containing a ONO2 ? group.

Nitroderivatives of polysaccharides

Glycosaminoglycans having high antithrombotic activity in vitro, obtained by various kinds of glycosaminoglycans supersulfated by the preparation of the salt of an organic base of the starting supersaturated glycosaminoglycan, by partial solvolytic desulfation of said salt and N-resulfation of said partially desulfated product.

Glycosaminoglycans having high antithrombotic activity

Polysaccharides and more in particular glycosaminoglycans, their mixtures, fractions and derivatives thereof are effective agents in the therapy of acute peripheral neuropathies of traumatic and ischemic origin and in the therapy of acute peripheral neuropathies of toxic origin.

Use of polysaccharides in acute peripheral neuropathies

By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Process for the isolation and purification of monosialoganglioside from

Heparins, heparin fractions or fragments, optionally salified with pharmaceutically acceptable cations, having molecular weight ranging from 1.000 to 30.000 D, characterized by an EDTA content lower than 0.1%, by the absence, in the .sup.1 H--NMR spectra, of the signals due to EDTA between 2.50 and 4.00 p.p.m. and substantially free from bleeding effect and optionally free from signals, in the .sup.13 C--NMR spectrum, from 80 to 86 ppm.

Process for preparing EDTA-free heparins, heparin fractions and fragments

Growing community of inventors

Milan, Italy

Benito Casu